Works matching IS 01676997 AND DT 2022 AND VI 40 AND IP 4

Results: 24

Rare ocular toxicity induced by pertuzumab/QL1209 in healthy chinese subjects: case reports and whole-exome sequencing analysis.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 861, doi. 10.1007/s10637-022-01256-0

By:

Ma, Junlong;
Chen, Wenjing;
Hu, Zhanqing;
Huang, Jie;
Guo, Chengxian;
Zou, Chan;
Yang, Guoping

Publication type:

Article

A phase Ib dose escalation study of oral monotherapy with KX2-391 in elderly patients with acute myeloid leukemia.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 773, doi. 10.1007/s10637-022-01255-1

By:

Kasner, Margaret T.;
Halloran, Molly B.;
Pan, Jonathan;
Ritchie, Ellen K.;
Fetterly, Gerald J.;
Kramer, Douglas;
Hangauer, David G.;
Thompson, James E.

Publication type:

Article

Autoimmune hemolytic anemia in patients with relapsed Hodgkin's lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 854, doi. 10.1007/s10637-022-01254-2

By:

Tao, Yiming;
Han, Jie;
Li, Yongsheng

Publication type:

Article

A lung adenocarcinoma patient harboring MET c. 3028 + 2 T >A variant sensitive to crizotinib treatment.

Published in:

2022

By:

Jiang, Rui;
Wei, Dongguang;
Tan, Yuan;
Duan, Qianqian

Publication type:

Letter

Selinexor synergizes with azacitidine to eliminate myelodysplastic syndrome cells through p53 nuclear accumulation.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 738, doi. 10.1007/s10637-022-01251-5

By:

Guo, Yixuan;
Liu, Zhaoyun;
Duan, Lixiang;
Shen, Hongli;
Ding, Kai;
Fu, Rong

Publication type:

Article

Exportin-1 is critical for cell proliferation and survival in adult T cell leukemia.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 718, doi. 10.1007/s10637-022-01250-6

By:

Ishikawa, Chie;
Mori, Naoki

Publication type:

Article

NSC305787, a pharmacological ezrin inhibitor, exhibits antineoplastic activity in pancreatic cancer cells.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 728, doi. 10.1007/s10637-022-01249-z

By:

Lipreri da Silva, Jean Carlos;
Carvalho, Maria Fernanda Lopes;
de Miranda, Livia Bassani Lins;
de Almeida, Bruna Oliveira;
Lima, Keli;
Machado-Neto, João Agostinho

Publication type:

Article

Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 789, doi. 10.1007/s10637-022-01248-0

By:

Wu, Wen-Chi;
Lin, Tzu-Yuan;
Chen, Ming‑Huang;
Hung, Yi‑Ping;
Liu, Chien-An;
Lee, Rheun‑Chuan;
Huang, Yi‑Hsiang;
Chao, Yee;
Chen, San-Chi

Publication type:

Article

Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 762, doi. 10.1007/s10637-022-01247-1

By:

LoRusso, Patricia;
Ratain, Mark J.;
Doi, Toshihiko;
Rasco, Drew W.;
de Jonge, Maja J. A.;
Moreno, Victor;
Carneiro, Benedito A.;
Devriese, Lot A.;
Petrich, Adam;
Modi, Dimple;
Morgan-Lappe, Susan;
Nuthalapati, Silpa;
Motwani, Monica;
Dunbar, Martin;
Glasgow, Jaimee;
Medeiros, Bruno C.;
Calvo, Emiliano

Publication type:

Article

Identifification of a novel LDLR-RET Fusion in Lung Adenocarcinoma.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 858, doi. 10.1007/s10637-022-01246-2

By:

Shi, Guanglin;
Luo, Yuyan;
Yu, Zhaonan;
Wang, Yue;
Zhu, Bojin

Publication type:

Article

A novel alectinib-sensitive CTNND1-ALK fusion in a lung adenocarcinoma patient: a case report.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 850, doi. 10.1007/s10637-022-01245-3

By:

Tian, Xiang;
Liao, Qiong;
Yang, Qidong;
Chen, Lin;
Xiao, Mingzhe;
Cheng, Yuanjian

Publication type:

Article

A small molecule inhibitor of VSIG-8 prevents its binding to VISTA.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 690, doi. 10.1007/s10637-022-01244-4

By:

Chen, Wenting;
Qie, Chenxin;
Hu, Xinlei;
Wang, Lanlan;
Jiang, Jingwei;
Liu, Wanmei;
Liu, Jun

Publication type:

Article

Effects of Nivolumab and Ipilimumab on the suppression of cisplatin resistant small cell lung cancer cells.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 709, doi. 10.1007/s10637-022-01243-5

By:

Chi, Wei;
Zhang, Lianyong;
Wang, Xue;
Li, Jingjing;
Li, Fei;
Ma, Yuxia;
Zhang, Qianyun

Publication type:

Article

Toxicity profile of anaplastic lymphoma kinase tyrosine kinase inhibitors for patients with non-small cell lung cancer: A systematic review and meta-analysis.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 831, doi. 10.1007/s10637-022-01242-6

By:

Tao, Yunxia;
Zhou, Yu;
Tang, Le;
Chen, Haizhu;
Feng, Yu;
Shi, Yuankai

Publication type:

Article

Effects of rifampicin on antineoplastic drug pyrotinib maleate pharmacokinetics in healthy subjects.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 756, doi. 10.1007/s10637-022-01241-7

By:

Cai, Ming-min;
Dou, Ting;
Tang, Lu;
Sun, Qiu-yue;
Zhai, Zi-hong;
Wang, Hui-ping;
Qian, Wei

Publication type:

Article

Synergistic activities of the histone deacetylase inhibitors with conventional cytotoxic chemotherapies in angiosarcomas.

Published in:

2022

By:

Zhang, Yingjun;
Wong, C. H.;
Loong, Herbert H. F.

Publication type:

Letter

A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 747, doi. 10.1007/s10637-022-01237-3

By:

Gan, Hui K.;
Parakh, Sagun;
Lee, F. T.;
Tebbutt, Niall C.;
Ameratunga, Malaka;
Lee, Sze Ting;
O'Keefe, Graeme J.;
Gong, Sylvia J.;
Vanrenen, Christine;
Caine, Jaren;
Giovannetti, Mara;
Murone, Carmel;
Scott, Fiona E.;
Guo, Nancy;
Burvenich, Ingrid J. G.;
Paine, Cameron;
Macri, Mary J.;
Kotsuma, Masakatsu;
Senaldi, Giorgio;
Venhaus, Ralph

Publication type:

Article

Practical consideration for successful sequential tumor biopsies in first-in-human trials.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 841, doi. 10.1007/s10637-022-01236-4

By:

Koyama, Takafumi;
Shimizu, Toshio;
Sato, Jun;
Katsuya, Yuki;
Iwasa, Satoru;
Kondo, Shunsuke;
Yoshida, Tatsuya;
Sudo, Kazuki;
Nishino, Makoto;
Takiguchi, Yuichi;
Yonemori, Kan;
Yamamoto, Noboru

Publication type:

Article

Palladium(II) Schiff base complex arrests cell cycle at early stages, induces apoptosis, and reduces Ehrlich solid tumor burden: a new candidate for tumor therapy.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 681, doi. 10.1007/s10637-022-01234-6

By:

Hassona, Shahd M.;
Saad, Entsar A.;
Kiwan, Hala A.;
Hassanien, Mohamed M.

Publication type:

Article

The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 810, doi. 10.1007/s10637-022-01232-8

By:

Meng, Li-Fang;
Huang, Jian-Feng;
Luo, Peng-Hui;
Huang, Shang-Xiao;
Wang, Han-Lei

Publication type:

Article

A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 782, doi. 10.1007/s10637-022-01230-w

By:

McLean, Luke S;
Morris, Tessa A;
Gramza, Ann;
Liu, Stephen;
Khan, Saad A.;
Colevas, A. Dimitrios;
Pearce, Tillman;
Rischin, Danny

Publication type:

Article

The radiosensitizing effect of β-Thujaplicin, a tropolone derivative inducing S-phase cell cycle arrest, in head and neck squamous cell carcinoma-derived cell lines.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 700, doi. 10.1007/s10637-022-01229-3

By:

Haas, Markus;
Lenz, Teresa;
Kadletz-Wanke, Lorenz;
Heiduschka, Gregor;
Jank, Bernhard J

Publication type:

Article

Signature constructed by glycolysis-immune-related genes can predict the prognosis of osteosarcoma patients.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 818, doi. 10.1007/s10637-022-01228-4

By:

Tian, Kangsong;
Qi, Wei;
Yan, Qian;
Lv, Ming;
Song, Delei

Publication type:

Article

Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.

Published in:

Investigational New Drugs, 2022, v. 40, n. 4, p. 798, doi. 10.1007/s10637-022-01227-5

By:

Michaeli, Daniel Tobias;
Mills, Mackenzie;
Michaeli, Thomas;
Miracolo, Aurelio;
Kanavos, Panos

Publication type:

Article